83 results about "Elisa assay" patented technology

The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytomery assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled antilymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (I) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between subcellular copartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing β-galactosidase fragments are provided. These β-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided.

The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E₂.

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

The present invention provides methods for diagnosing several types of diseases. Specifically, the present disclosure provides a panel of diagnostic genes, the differential expression of whose mRNAs or proteins in the sample of a subject indicates the presence of the disease in the subject. The methods involve extracting mRNAs or proteins from the sample and performing gene expression profiling assays such as microarray assay, RT-PCR oligonucleotide binding array, quantitative RT-PCR assay, proteomics assay, and/or ELISA assay.

The invention provides a neosporosis rELISA antibody assay kit. The neosporosis recombinant enzyme-linked immunosorbent assay (rELISA) antibody assay kit is characterized in that designing a primer set according to a neospora caninum NcSRS2 gene of the GenBank, introducing the primer set to an enzyme digestion site, removing a signal peptide zone of an NcSRS2 protein, extracting a DNA from Xinjiang cow positive serum, carrying out polymerase chain reaction (PCR) amplification of the DNA to obtain a tNcSRS2 genetic fragment having length of 975bp, cloning the tNcSRS2 genetic fragment into a pMD-18-T carrier, carrying out enzyme digestion and sequencing, further directionally connecting the desired fragment obtained by the previous step to a pGEX-4T-2 expression carrier, transferring the pGEX-4T-2 expression carrier with the desired fragment into escherichia coli, carrying out inducible expression and purification, wherein expressed fusion protein molecular weight is about 62kDa, and carrying out ELISA antigen coating by the expressed fusion protein to obtain the neosporosis rELISA antibody assay kit. A use method of the neosporosis rELISA antibody assay kit comprises the following steps that a coated enzyme label reaction plate is taken out, is subjected to first washing, is enclosed, is subjected to second washing, is added with a sample needing to be detected, is subjected to third washing, is added with a secondary antibody, is subjected to fourth washing, and undergoes a color reaction; and when the color reaction is finished, an OD450/630 value of the coated enzyme label reaction plate is read and a result is determined. Compared with a commercial ELISA assay kit, the neosporosis rELISA antibody assay kit has a higher coincidence rate above 95% The neosporosis rELISA antibody assay kit also is suitable for the ELISA of a neospora caninum antibody in ruminant serum and blood plasma.

Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described for use in detecting PrPsc in biological samples. In particular, ELISA assays are described.

Improved immunoassays for the protection of antibodies against Lawsonia intracellularis are provided which permit rapid, easy detection of low concentrations of anti-Lawsonia antibodies in animal-derived specimens. The preferred assay is an ELISA assay employing an antigenic extract of L. intracellularis lipopolysaccharide.

The present invention relates to non-isotopic immunoassays for thiopurine methyltransferase (TPMT). The immunoassays of this invention may be homogenous or heterogenous, in which detection of the TPMT-catalyzed reaction product relies upon specific binding of antibody to 6-MMP or other TPMT-catalyzed reaction products. Preferred embodiments of this invention include a Rapid Immunomigration Cassette and an assay carried out in ELISA assay format.

The invention discloses an application of Loureirin B in the preparation of a Kv1.3 channel blocker and provides a new drug approach for treating autoimmune diseases. The Loureirin B contains clear components and quality of the Loureirin B is controllable. The Loureirin B can effectively inhibit a Kv1.3 potassium channel, thus effectively treating various autoimmune diseases. Through various verification means of patch clamp experiment, calcium imaging techniques, ELISA assay and manufacturing of animal models of autoimmune encephalitis, rheumatoid arthritis and the like, it is found that the Loureirin B has a good therapeutical effect on autoimmune diseases at the overall level, can effectively overcome side effects of traditional therapeutics such as adrenocortical hormone and the like and can maintain normal protective immune responses of patients.

The invention herein is directed to immunoassays for the detection of Aβ42 oligomers. The inventive assays are based on the observations herein that the presence of Aβ42 oligomers in a preparation is directly related to a decrease in a C-terminal (CT) immunosignal and a correlated increase in an N-terminal (NT) immunosignal, relative to the immunosignal generated in the absence of Aβ42 oligomers, in an Aβ42 CT and NT ELISA assay and an Aβ42 CT AlphaLISA assay. The invention herein involves the use of these assays alone or in combination to screen for inhibitors of Aβ42 oligomerization.

Improved ELISA assay formats are described that provide for effective measurement of desmosine, an elastin degradation product, in urine samples. The urine samples can be effectively introduced into the assay with little or no sample preparation. The competitive ELISA assay based on high titer polyclonal antibodies is suitable for commercial application. Desirable antibodies can be generated using desmosine bound to a protein or the like using a protein crosslinking agent. The desmosine assay are found to be useful for the diagnosis of aortic aneurysms in which desmosine levels of patients with aortic aneurysms have been found to be significantly elevated relative to a control group.

The invention pertains to methods for measuring different forms of human adiponectin that are present in human plasma/serum, and more specifically methods are based on an ELISA assay that utilizes different monoclonal antibodies directed against adiponectin, in combination with different polyclonal antibodies directed against different domains of human adiponectin. The invention also provides unique isoforms of adiponectin and antibodies thereto, including polyclonal and monoclonal antibodies.

The present disclosure refers to an enzyme-linked immunosorbent assay (ELISA) plate comprising at least one row of reaction chambers, wherein the reaction chambers in the same row are in fluid communication with each other. Also enclosed is a system for detecting one or more target analytes comprising an ELISA plate as described herein, a plurality of magnetic beads and a magnet configured to cooperate with the magnetic beads. Also encompassed is a method of performing an ELISA assay which comprises of moving magnetic beads through subsequent reaction chambers, wherein the reaction chambers are alternatingly filled with a non-aqueous liquid, such as silicone oil, and aqueous ELISA reagents.

The invention discloses a preparation method of a recombinant protein IE1-coated ELISA (Enzyme linked immune sorbent assay) reaction plate and an assay kit for quantitatively detecting HCMV (human cytomegalovirus) neutralized antibody in human plasma and relates to a preparation method of a novel recombinant antigen IE1-coated ELISA reaction plate and a prepared ELISA assay kit for quantitatively detecting HCMV neutralized antibody in human plasma based on the preparation method of the novel recombinant antigen IE1-coated ELISA reaction plate. The preparation method comprises the following steps: preparing specificity recombinant HCMVIE1 antigen, purifying protein, coating the ELISA reaction plate and assembling the ELISA assay kit for quantitatively detecting HCMV neutralized antibody in human plasma. Compared with the other commercial ELISA assay kit, the ELISA assay kit disclosed by the invention can highly specifically, sensitively and rapidly detect IgG antibody titer with neutralized HCMV specificity in plasma and the detection result is highly consistent with that of a micro neutralization experiment. The preparation method of the recombinant protein IE1-coated ELISA (Enzyme linked immune sorbent assay) reaction plate and the assay kit for quantitatively detecting HCMV (human cytomegalovirus) neutralized antibody in human plasma are mainly used for screening high-titer HCMV intravenous injected gamma globulin production raw materials for laboratory research, clinical screening and blood product enterprises screening.

The invention relates to a reagent cartridge 10 for an assembly for selectively performing a clinical chemical test or an ELISA assay comprising a housing 11 having at least one cavity 12, 13, 14 that contains a reaction or diluting component and having a recess 15 in which a solid phase 20 to which an antigen or antibody can be coupled is inserted into the recess 15 of the housing 11. It is particularly advantageous if the reagent cartridge 10 comprises three cavities 12, 13, 14 and the reagent cartridge 10 can be used for analyzing clinical chemical parameters, for analyzing immunodiagnostic parameters, for providing additional reagents, and as a diluting cartridge.

An apparatus and method to achieve manipulation of particles and/or solutions through the induction of electromagnetic fields inside liquid contained inside vessels are disclosed. A “vessel” denotes specifically either a microtitter plate (microplate or well-plate, 1536, 3456 or any other format) well or hybridization solution placed on microarrays for hybridization experiment purposes or more generally any volume containing liquid solution. The manipulation is performed by bringing the active part of the device into contact with the fluidic solution, wherein electromagnetic fields and/or induced fluid flow are used to perform specific manipulations including transport, separation, concentration, mixing, reaction and electroporation. The invention can be used to enhance processing in a number of standard assays and protocols, including the Polymerase Chain Reaction, kinase-based assays, ELISA assays and electroporation.